MyoKardia Inc logo

MYOK - MyoKardia Inc Share Price

$224.91 0.0  0.0%

Last Trade - 16/11/20

Sector
Healthcare
Size
Large Cap
Market Cap £8.83bn
Enterprise Value £8.17bn
Revenue £n/a
Position in Universe th / 6547
Bullish
Bearish
Unlock MYOK Revenue
Momentum
Relative Strength (%)
1m -0.64%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
5.92 14.2 42.0 11.4 33.6 0.000 18.4 -100.0%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Myokardia Inc revenues was not reported. Net loss decreasedless than 1% to $218.2M., offset by Research anddevelopment - Balancing increase of 53% to $139.1M(expense), General and administrative - Balancing increaseof 57% to $49.7M (expense), Stock-based Compensation in R&Dincrease of 55% to $16.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for MYOK
Graphical History

Revenue

MYOK Revenue Unlock MYOK Revenue

Net Income

MYOK Net Income Unlock MYOK Revenue

Normalised EPS

MYOK Normalised EPS Unlock MYOK Revenue

PE Ratio Range

MYOK PE Ratio Range Unlock MYOK Revenue

Dividend Yield Range

MYOK Dividend Yield Range Unlock MYOK Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MYOK EPS Forecasts Unlock MYOK Revenue
Profile Summary

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated June 8, 2012
Public Since October 29, 2015
No. of Shareholders: 6
No. of Employees: 318
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue 53,322,904
Free Float (0.0%)
Eligible for
ISAs
SIPPs
MYOK Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MYOK
Upcoming Events for MYOK
Frequently Asked Questions for MyoKardia Inc
What is the MyoKardia Inc share price?

As of 16/11/20, shares in MyoKardia Inc are trading at $224.91, giving the company a market capitalisation of £8.83bn. This share price information is delayed by 15 minutes.

How has the MyoKardia Inc share price performed this year?

Shares in MyoKardia Inc are currently trading at $224.91 and the price has moved by 0.309k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the MyoKardia Inc price has moved by 0.259k% over the past year.

What are the analyst and broker recommendations for MyoKardia Inc?

Of the analysts with advisory recommendations for MyoKardia Inc, there are there are currently 0 "buy" , 9 "hold" and 0 "sell" recommendations. The overall consensus recommendation for MyoKardia Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will MyoKardia Inc next release its financial results?

MyoKardia Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the MyoKardia Inc dividend yield?

MyoKardia Inc does not currently pay a dividend.

Does MyoKardia Inc pay a dividend?

MyoKardia Inc does not currently pay a dividend.

When does MyoKardia Inc next pay dividends?

MyoKardia Inc does not currently pay a dividend.

How do I buy MyoKardia Inc shares?

To buy shares in MyoKardia Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of MyoKardia Inc?

Shares in MyoKardia Inc are currently trading at $224.91, giving the company a market capitalisation of £8.83bn.

Where are MyoKardia Inc shares listed? Where are MyoKardia Inc shares listed?

Here are the trading details for MyoKardia Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: MYOK
What kind of share is MyoKardia Inc?

We were not able to load our ranking data for MyoKardia Inc

Is there a MyoKardia Inc share price forecast 2021?

Shares in MyoKardia Inc are currently priced at $224.91. At that level they are trading at 4.5% premium to the analyst consensus target price of 0.00.

Analysts covering MyoKardia Inc currently have a consensus Earnings Per Share (EPS) forecast of -5.659 for the next financial year.

How can I tell whether the MyoKardia Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MyoKardia Inc. Over the past six months, the relative strength of its shares against the market has been 77.81%. At the current price of $224.91, shares in MyoKardia Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the MyoKardia Inc PE Ratio?

We were not able to find PE ratio data for MyoKardia Inc.

Who are the key directors of MyoKardia Inc?

We were unable to find the directors for MyoKardia Inc.

Who are the major shareholders of MyoKardia Inc?

Here are the top five shareholders of MyoKardia Inc based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 14.62% (7.80m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.56% (4.56m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.76% (3.61m shares)
Baker Bros. Advisors LP Hedge Fund
Percentage owned: 5.93% (3.16m shares)
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund
Percentage owned: 3.53% (1.88m shares)
Similar to MYOK
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.